Company intelligence / Profile preview

Guangzhou Nanxin Pharmaceutical

Guangzhou, Guangdong Sheng / Province, Chinacrunchbase.com ↗

Ownership: Private
Development stage: Commercial

Overview

Guangzhou Nanxin Pharmaceutical is a Chinese pharmaceutical company focused on the development and commercialization of small molecule drugs. Its portfolio includes approved products such as benazepril hydrochloride/hydrochlorothiazide for hypertension and peramivir for influenza. The company also has preclinical programs targeting infectious diseases and metabolic disorders, including candidates modulating TGF-beta 1 signaling. It is active in clinical trials with at least one program reaching Phase 2.

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

7 assets

NX-2016

Preclinical

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Guangzhou Nanxin Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Nanxin Pharmaceutical.

Explore the full profile